

#4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Kranz, et al.

Serial No.: 09/731,242

Confirmation No.: 8588


Filed: December 6, 2000

For: HIGH AFFINITY TCR PROTEINS AND
METHODS



Group Art Unit: 1645

: Examiner: not assigned



STATEMENT UNDER 37 C.F.R. § 1.821-825

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

Applicants herewith submit a replacement paper copy of the Sequence Listing as pages 1-16. Applicants also submit a write-protected diskette copy of the replacement Sequence Listing in computer-readable form as required by 37 C.F.R. § 1.821 (e).

The enclosed computer-readable sequence listing and paper copy of the sequence listing add fields <220> through <223> for all sequences and add the continuing data for application number 09/388,008. No new matter is added, and the amendments are fully supported by the specification as filed.


In compliance with 37 C.F.R. § 1.821 (f), the undersigned states that the content of the paper copy and the computer-readable copy of the Sequence Listing are the same.

09/731,242

This replacement Sequence Listing is believed to comply with the requirements of 37 C.F.R. 1.821-1.825. This submission is intended to be a complete reply to the requirements in the Notice to File Missing Parts of Nonprovisional Application.

It is believed that this submission does not require the payment of any fees. If this is incorrect, however, please charge any requisite fees to Deposit Account No. 07-1969.

Respectfully submitted,



Susan K. Doughty
Reg. No. 43,595

GREENLEE, WINNER AND SULLIVAN, P.C.
5370 Manhattan Circle, Suite 201
Boulder, CO 80303
Telephone: (303) 499-8080
Facsimile: (303) 499-8089
E-mail: winner@greenwin.com

Attorney Docket No.: 89-99
nnr:5/9/01



SEQUENCE LISTING

<110> KRANZ,
WITTRUP, K. DANE
HOLLER, PHILLIP

<120> HIGH AFFINITY TCR PROTEINS AND METHODS

<130> 89-99

<140> NOT ASSIGNED

<141> 2000-12-06

<150> US 60/169,179

<151> 1999-12-06

<150> US 09/009,388

<151> 1998-01-20

<160> 53

<170> PatentIn version 3.0

<210> 1

<211> 4

<212> PRT

<213> ARTIFICIAL SEQUENCE

<220>

<221> misc_feature

<222> ()..()

<223> null peptide

<400> 1

Met Cys Met Val

1

<210> 2

<211> 4

<212> PRT

<213> ARTIFICIAL SEQUENCE

<220>

<221> misc_feature

<222> ()..()

<223> incubation peptide

<400> 2

Ser Ile Tyr Arg

1

<210> 3
 <211> 24
 <212> PRT
 <213> ARTIFICAL SEQUENCE

<220>
 <221> misc_feature
 <222> ()..()
 <223> upstream primer

<400> 3

Gly Gly Cys Ala Gly Cys Cys Cys Cys Ala Thr Ala Ala Ala Cys Ala
 1 5 10 15
 Cys Ala Cys Ala Gly Thr Ala Thr
 20

<210> 4
 <211> 74
 <212> PRT
 <213> ARTIFICIAL SEQUENCE

<220>
 <221> misc_feature
 <222> ()..()
 <223> downstream primer

<400> 4

Cys Thr Thr Thr Thr Gly Thr Gly Cys Cys Gly Gly Ala Thr Cys Cys
 1 5 10 15
 Ala Ala Ala Thr Gly Thr Cys Ala Gly Ser Asn Asn Ser Asn Asn Ser
 20 25 30
 Asn Asn Ser Asn Asn Ser Asn Asn Gly Cys Thr Cys Ala Cys Ala Gly
 35 40 45
 Cys Ala Cys Ala Gly Ala Ala Gly Thr Ala Cys Ala Cys Gly Gly Cys
 50 55 60
 Cys Gly Ala Gly Thr Cys Gly Cys Thr Cys
 65 70

<210> 5
 <211> 8
 <212> PRT
 <213> ARTIFICIAL SEQUENCE

<220>
 <221> misc_feature
 <222> ()..()
 <223> binding peptide

<400> 5

Ser Ile Tyr Arg Tyr Tyr Gly Leu
1 5

<210> 6

<211> 8

<212> PRT

<213> ARTIFICIAL SEQUENCE

<220>

<221> misc_feature

<222> ()..()

<223> screening peptide

<400> 6

Glu Gln Tyr Lys Phe Tyr Ser Val
1 5

<210> 7

<211> 7

<212> PRT

<213> ARTIFICIAL SEQUENCE

<220>

<221> misc_feature

<222> ()..()

<223> CDR3alpha sequence

<400> 7

Ser Gly Phe Ala Ser Ala Leu
1 5

<210> 8

<211> 7

<212> PRT

<213> ARTIFICIAL SEQUENCE

<220>

<221> misc_feature

<222> ()..()

<223> CDR3alpha sequence

<400> 8

Ser Ser Tyr Gly Asn Tyr Leu
1 5

<210> 9
<211> 7
<212> PRT
<213> ARTIFICIAL SEQUENCE

<220>
<221> misc_feature
<222> ()..()
<223> CDR3alpha sequence

<400> 9

Ser Arg Arg Gly His Ala Leu
1 5

<210> 10
<211> 7
<212> PRT
<213> ARTIFICIAL SEQUENCE

<220>
<221> misc_feature
<222> ()..()
<223> CDR3alpha sequence

<400> 10

Ser Ser Arg Gly Thr Ala Leu
1 5

<210> 11
<211> 7
<212> PRT
<213> ARTIFICIAL SEQUENCE

<220>
<221> misc_feature
<222> ()..()
<223> CDR3alpha sequence

<400> 11

Ser His Phe Gly Thr Arg Leu
1 5

<210> 12
<211> 7
<212> PRT
<213> ARTIFICIAL SEQUENCE

<220>
<221> misc_feature
<222> ()..()
<223> CDR3alpha sequence

<400> 12

Ser Met Phe Gly Thr Arg Leu
1 5

<210> 13

<211> 7

<212> PRT

<213> ARTIFICIAL SEQUENCE

<220>

<221> misc_feature

<222> ()..()

<223> CDR3alpha sequence

<400> 13

Ser His Gln Gly Arg Tyr Leu
1 5

<210> 14

<211> 7

<212> PRT

<213> ARTIFICIAL SEQUENCE

<220>

<221> misc_feature

<222> ()..()

<223> CDR3alpha sequence

<400> 14

Ser Tyr Leu Gly Leu Arg Leu
1 5

<210> 15

<211> 7

<212> PRT

<213> ARTIFICAL SEQUENCE

<220>

<221> misc_feature

<222> ()..()

<223> CDR3alpha sequence

<400> 15

Ser Lys His Gly Ile His Leu
1 5

<210> 16
<211> 7
<212> PRT
<213> ARTIFICIAL SEQUENCE

<220>
<221> misc_feature
<222> ()..()
<223> CDR3alpha sequence

<400> 16

Ser Leu Thr Gly Arg Tyr Leu
1 5

<210> 17
<211> 7
<212> PRT
<213> ARTIFICIAL SEQUENCE

<220>
<221> misc_feature
<222> ()..()
<223> CDR3alpha sequence

<400> 17

Ser Leu Pro Pro Pro Leu Leu
1 5

<210> 18
<211> 7
<212> PRT
<213> ARTIFICIAL SEQUENCE

<220>
<221> misc_feature
<222> ()..()
<223> CDR3alpha sequence

<400> 18

Ser Ile Pro Thr Pro Ser Leu
1 5

<210> 19
<211> 7
<212> PRT
<213> ARTIFICIAL SEQUENCE

<220>
<221> misc_feature
<222> ()..()
<223> CDR3alpha sequence

<400> 19

Ser Asn Pro Pro Pro Leu Leu
1 5

<210> 20
<211> 7
<212> PRT
<213> ARTIFICIAL SEQUENCE

<220>
<221> misc_feature
<222> ()..()
<223> CDR3alpha sequence

<400> 20

Ser Asp Pro Pro Pro Leu Leu
1 5

<210> 21
<211> 7
<212> PRT
<213> ARTIFICIAL SEQUENCE

<220>
<221> misc_feature
<222> ()..()
<223> CDR3alpha sequence

<400> 21

Ser Ser Pro Pro Pro Arg Leu
1 5

<210> 22
<211> 7
<212> PRT
<213> ARTIFICIAL SEQUENCE

<220>
<221> misc_feature
<222> ()..()
<223> CDR3alpha sequence

<400> 22

Ser Ala Pro Pro Pro Ile Leu
1 5

<210> 23
<211> 7
<212> PRT
<213> ARTIFICIAL SEQUENCE

<220>
<221> misc_feature
<222> ()..()
<223> CDR3alpha sequence

<400> 23

Ser Gly Thr His Pro Phe Leu
1 5

<210> 24
<211> 7
<212> PRT
<213> ARTIFICIAL SEQUENCE

<220>
<221> misc_feature
<222> ()..()
<223> CDR3alpha sequence

<400> 24

Ser Gly His Leu Pro Phe Leu
1 5

<210> 25
<211> 7
<212> PRT
<213> ARTIFICIAL SEQUENCE

<220>
<221> misc_feature
<222> ()..()
<223> CDR3alpha sequence

<400> 25

Ser Asp Ser Lys Pro Phe Leu
1 5

<210> 26
<211> 7
<212> PRT
<213> ARTIFICIAL SEQUENCE

<220>
<221> misc_feature
<222> ()..()
<223> CDR3alpha sequence

<400> 26

Ser Ser Asp Arg Pro Tyr Leu
1 5

<210> 27

<211> 7

<212> PRT

<213> ARTIFICIAL SEQUENCE

<220>

<221> misc_feature

<222> ()..()

<223> CDR3alpha sequence

<400> 27

Ser Leu Glu Arg Pro Tyr Leu
1 5

<210> 28

<211> 7

<212> PRT

<213> ARTIFICIAL SEQUENCE

<220>

<221> misc_feature

<222> ()..()

<223> CDR3alpha sequence

<400> 28

Ser Arg Glu Ala Pro Tyr Leu
1 5

<210> 29

<211> 7

<212> PRT

<213> ARTIFICIAL SEQUENCE

<220>

<221> misc_feature

<222> ()..()

<223> CDR3alpha sequence

<400> 29

Ser Leu His Arg Pro Ala Leu
1 5

<210> 30
<211> 7
<212> PRT
<213> ARTIFICIAL SEQUENCE

<220>
<221> misc_feature
<222> ()..()
<223> CDR3alpha sequence

<400> 30

Ser Leu His Arg Pro Ala Leu
1 5

<210> 31
<211> 7
<212> PRT
<213> ARTIFICIAL SEQUENCE

<220>
<221> misc_feature
<222> ()..()
<223> CDR3alpha sequence

<400> 31

Ser Ser Asn Arg Pro Ala Leu
1 5

<210> 32
<211> 7
<212> PRT
<213> ARTIFICIAL SEQUENCE

<220>
<221> misc_feature
<222> ()..()
<223> CDR3alpha sequence

<400> 32

Ser Thr Asp Arg Pro Ser Leu
1 5

<210> 33
<211> 7
<212> PRT
<213> ARTIFICIAL SEQUENCE

<220>
<221> misc_feature
<222> ()..()
<223> CDR3alpha sequence

<400> 33

Ser Gly Ser Arg Pro Thr Leu
1 5

<210> 34

<211> 7

<212> PRT

<213> ARTIFICIAL SEQUENCE

<220>

<221> misc_feature

<222> ()..()

<223> CDR3alpha sequence

<400> 34

Ser Leu Val Thr Pro Ala Leu
1 5

<210> 35

<211> 7

<212> PRT

<213> ARTIFICIAL SEQUENCE

<220>

<221> misc_feature

<222> ()..()

<223> CDR3alpha sequence

<400> 35

Ser Ala Thr Ser Pro Ala Leu
1 5

<210> 36

<211> 7

<212> PRT

<213> ARTIFICIAL SEQUENCE

<220>

<221> misc_feature

<222> ()..()

<223> CDR3alpha sequence

<400> 36

Ser Ser Ile Asn Pro Ala Leu
1 5

<210> 37
<211> 7
<212> PRT
<213> ARTIFICIAL SEQUENCE

<220>
<221> misc_feature
<222> ()..()
<223> CDR3alpha sequence

<400> 37

Ser Ala Ser Tyr Pro Ser Leu
1 5

<210> 38
<211> 7
<212> PRT
<213> ARTIFICIAL SEQUENCE

<220>
<221> misc_feature
<222> ()..()
<223> CDR3alpha sequence

<400> 38

Ser Arg Trp Thr Ser Gly Leu
1 5

<210> 39
<211> 7
<212> PRT
<213> ARTIFICIAL SEQUENCE

<220>
<221> misc_feature
<222> ()..()
<223> CDR3alpha sequence

<400> 39

Ser Gly Ser Arg Pro Ala Leu
1 5

<210> 40
<211> 7
<212> PRT
<213> ARTIFICIAL SEQUENCE

<220>
<221> misc_feature
<222> ()..()
<223> CDR3alpha sequence

<400> 40

Ser Leu Thr His His Phe Leu
1 5

<210> 41

<211> 7

<212> PRT

<213> ARTIFICIAL SEQUENCE

<220>

<221> misc_feature

<222> ()..()

<223> CDR3alpha sequence

<400> 41

Ser Met Thr His His Phe Leu
1 5

<210> 42

<211> 7

<212> PRT

<213> ARTIFICIAL SEQUENCE

<220>

<221> misc_feature

<222> ()..()

<223> CDR3alpha sequence

<400> 42

Ser Leu Ser Arg Pro Tyr Leu
1 5

<210> 43

<211> 7

<212> PRT

<213> ARTIFICIAL SEQUENCE

<220>

<221> misc_feature

<222> ()..()

<223> CDR3alpha sequence

<400> 43

Ser Leu Thr Arg Pro Tyr Leu
1 5

<210> 44
<211> 7
<212> PRT
<213> ARTIFICIAL SEQUENCE

<220>
<221> misc_feature
<222> ()..()
<223> CDR3alpha sequence

<400> 44

Ser Thr Tyr Arg His Tyr Leu
1 5

<210> 45
<211> 7
<212> PRT
<213> ARTIFICIAL SEQUENCE

<220>
<221> misc_feature
<222> ()..()
<223> CDR3alpha sequence

<400> 45

Ser Gly Leu Ala Arg Pro Leu
1 5

<210> 46
<211> 7
<212> PRT
<213> ARTIFICIAL SEQUENCE

<220>
<221> misc_feature
<222> ()..()
<223> CDR3alpha sequence

<400> 46

Ser Leu His Arg Pro Ala Leu
1 5

<210> 47
<211> 7
<212> PRT
<213> ARTIFICIAL SEQUENCE

<220>
<221> misc_feature
<222> ()..()
<223> CDR3alpha sequence

<400> 47

Ser Gly Thr His Pro Phe Leu
1 5

<210> 48

<211> 7

<212> PRT

<213> ARTIFICIAL SEQUENCE

<220>

<221> misc_feature

<222> ()..()

<223> CDR3beta sequence

<400> 48

Gly Gly Gly Gly Thr Leu Tyr
1 5

<210> 49

<211> 7

<212> PRT

<213> ARTIFICIAL SEQUENCE

<220>

<221> misc_feature

<222> ()..()

<223> CDR3beta sequence

<400> 49

Gly Gly Gly Gly Val Leu Tyr
1 5

<210> 50

<211> 7

<212> PRT

<213> ARTIFICIAL SEQUENCE

<220>

<221> misc_feature

<222> ()..()

<223> CDR3beta sequence

<400> 50

Gly Leu Gly Gly Ile Leu Tyr
1 5

<210> 51
<211> 7
<212> PRT
<213> ARTIFICIAL SEQUENCE

<220>
<221> misc_feature
<222> ()..()
<223> CDR3beta sequence

<400> 51

Gly Gln Gly Gly Val Leu Tyr
1 5

<210> 52
<211> 7
<212> PRT
<213> ARTIFICIAL SEQUENCE

<220>
<221> misc_feature
<222> ()..()
<223> CDR3beta sequence

<400> 52

Gly Ser Gly Gly Ile Ile Tyr
1 5

<210> 53
<211> 7
<212> PRT
<213> ARTIFICIAL SEQUENCE

<220>
<221> misc_feature
<222> ()..()
<223> CDR3beta sequence

<400> 53

Gly Gly Gly Gly Ile Leu Tyr
1 5